Our study provided potential molecular mechanisms why the combination of pyrotinib, letrozole, and dalpiciclib could achieve satisfactory clinical response and found CALML5 as a potential risk factor in the treatment of HER2+HR+ breast cancer. This evidence concerns the gene CALML5 and breast carcinoma.